Free Access
Issue
J Extra Corpor Technol
Volume 47, Number 4, December 2015
Page(s) 223 - 227
DOI https://doi.org/10.1051/ject/201547223
Published online 15 December 2015
  1. Donahue BS, Factor V. Leiden and perioperative risk. Anesth Analg. 2004;98:1623–34. [CrossRef] [PubMed] [Google Scholar]
  2. Moor E, Silveira A, van’t Hooft F, et al. Coagulation factor V (Arg506→Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Thromb Haemost. 1998;80:220–4. [CrossRef] [PubMed] [Google Scholar]
  3. Massoudy P, Thielmann M, Muller-Beissenhirtz H, et al. Thrombophilia in cardiac surgery-patients with symptomatic factor V Leiden. J Card Surg. 2009;24:379–82. [CrossRef] [Google Scholar]
  4. Kujovich JL, Factor V. Leiden thrombophilia. Genet Med. 2011;13:1–16. [CrossRef] [Google Scholar]
  5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–8. [CrossRef] [PubMed] [Google Scholar]
  6. Castoldi E, Rosing J, Factor V. Leiden: A disorder of factor V anticoagulant function. Curr Opin Hematol. 2004;11:176–81. [CrossRef] [PubMed] [Google Scholar]
  7. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521–4. [CrossRef] [PubMed] [Google Scholar]
  8. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost. 2004;2:430–6. [CrossRef] [Google Scholar]
  9. Inangil G, Yedekci AE, Sen H. Coronary artery bypass graft surgery in a patient with concomitant factor V leiden mutation and thromboangiitis obliterans. J Cardiothorac Vasc Anesth. 2012;26: e42–3. [CrossRef] [Google Scholar]
  10. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George ALJr, Factor V. Leiden protects against blood loss and transfusion after cardiac surgery. Circulation. 2003;107:1003–8. [CrossRef] [PubMed] [Google Scholar]
  11. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(Suppl):258S–75S. [CrossRef] [PubMed] [Google Scholar]
  12. Stammers AH, Dorion RP, Trowbridge C, et al. Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: A case report. Perfusion. 2005;20:115–20. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.